How to Buy Xoma Royalty Stock
Xoma Royalty Corp
XOMA Royalty Corp. operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health.
Xoma Royalty stock last closed at $41.54, down 0.24% from the previous day, and has increased 51.16% in one year. It has overperformed other stocks in the Biotechnology industry by 1.28 percentage points. Xoma Royalty stock is currently +86.28% from its 52-week low of $22.30, and -2.97% from its 52-week high of $42.81.
As of May 19, 2026, there are 12.54M XOMA shares outstanding. The market value of XOMA is $520.95M. In the last 24 hours, 122,000 XOMA shares were traded.
How to Buy Xoma Royalty Stock
Wondering how to invest in Xoma Royalty stock? Here's how.
- Figure out where to buy Xoma Royalty stock: You need to decide on a stock brokerage, but don't worry - we've analyzed dozens of online stock brokerages and apps to help you decide where to buy Xoma Royalty stock.
- Sign up for your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Deposit funds into your investment account: Select your payment method and add your details.
- Evaluate Xoma Royalty stock: The Xoma Royalty ticker symbol is XOMA. Is Xoma Royalty stock a good investment? Should you buy shares of XOMA? How do XOMA's underlying business fundamentals look? Do top analysts think Xoma Royalty is a good buy? Why has XOMA's stock price moved recently? (Hint: Our stock research website can help you understand if XOMA is a good stock to buy).
- Execute your XOMA buy order: Decide if you will purchase XOMA shares at the current market price or use a limit order to buy XOMA stock at a specific price.
- Keep tabs on your XOMA position: Create a watchlist to track your new investment in Xoma Royalty stock.
Step 1: Figure out where to buy Xoma Royalty stock
You will need an online brokerage account to access the NASDAQ market and buy XOMA shares.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best brokerage. Here's why:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to world financial markets: From Technology to Energy, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro boasts a community of more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've chosen your brokerage, you'll need to fill out some personal details so you are able to invest in XOMA stock today.
How to Open a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal info to start your new trading account.
- Send your info by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have opened your account on the best free stock trading app, you can securely and quickly fund your account:
Check out the tutorial below if you need help depositing money into your new investment account.
Step 4: Evaluate Xoma Royalty stock
After you have decided on the best place to buy Xoma Royalty stock, it's critical to analyze their stock prior to investing, so you actually wrap your head around the risk as well as the opportunity.
Overview of key XOMA info
Fundamentals of Xoma Royalty
WallStreetZen was built to help part-time investors do more accurate fundamental analysis in less time.
You can view all of the due diligence checks on XOMA's stock page.
Is XOMA stock undervalued or overvalued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge XOMA's fair value.
Using relative valuations measures:
- XOMA could be overvalued based on its P/E ratio of 25.18x, relative to Biotechnology industry P/E ratio of 20.21x
- XOMA could be overvalued based on its P/B ratio of 5.61x, relative to Biotechnology industry P/B ratio of 4.72x
You can do additional valuation analysis on XOMA's stock here.
Is XOMA a healthy company?
Signs that XOMA is financially healthy:
- There are more short-term assets than short-term liabilities on the XOMA balance sheet.
- XOMA profit margin has gone up from -30.3% to 41.1% in the past year.
Signs that XOMA is not financially healthy:
- XOMA earnings of $32.98M is not sufficient to cover its interest payments.
- XOMA's operating cash flow of $6.79M allows it to safely service it's debt of $124.73M.
- XOMA has a relatively high debt to equity ratio of 1.71.
- There are more long-term liabilities than short-term assets on the XOMA balance sheet.
- Total XOMA debt is higher than 5 years ago, relative to shareholder equity.
Is XOMA stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 4 Equities analysts who give recommendations on XOMA, the consensus analyst rating on XOMA is a Buy
Please note that analyst forecasts are not recommendations, nor are they investment advice.
You can dive deeper into what analysts are forecasting on the Xoma Royalty stock forecast page.
XOMA Momentum
XOMA Growth Numbers
Last year, XOMA earnings were $19.95M. Over the past 5 year, XOMA's earnings have increased by 23.26% per year. This was faster than the Biotechnology industry average of 12.11%.
Last year, XOMA revenue was $48.56M. Over the last 5 year, XOMA's revenue has increased by 10.89% per year. This was slower than the Biotechnology industry average of 29.7%.
Learn more about XOMA's earnings and revenue performance here.
Who is buying/selling XOMA?
In the last 12 months, executives and large shareholders at XOMA have bought more shares than they have sold.
Bvf Partners L P, 10% Owner of XOMA, was the latest XOMA insider to buy. They bought $9,321,390.00 worth of XOMA shares on May 14, 2026.
Research more about who owns XOMA shares here.
Can I rely on XOMA as an income stream?
No, Xoma Royalty doesn't provide an income stream by paying out dividends.
What do other traders have to say about XOMA?
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Execute your XOMA buy order
There are two primary options:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are generally sufficient. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at a given price limit, use a limit order.
Hit the Open Trade button and eToro will place the order.
If you want additional help with investing in stocks on eToro, click the helpful video below:
Step 6: Keep tabs on your XOMA position
Now that you own some XOMA shares, you'll want to keep up with your investment.
Put XOMA on a watchlist to track your XOMA stock.
XOMA Feed
How to Buy Stock in Xoma Royalty
To summarize, here are the 6 steps to buy Xoma Royalty stock:
- Figure out where to buy Xoma Royalty stock
- Sign up for your brokerage account
- Deposit funds into your investment account
- Evaluate Xoma Royalty stock
- Execute your XOMA buy order
- Keep tabs on your XOMA position
If you are looking for a online brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you want to keep track of your new investment in Xoma Royalty, create a watchlist today.
Other Stock Buying Guides You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.